Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale

PREVENTABLE Trial Research Group, Jacob Joseph, Nicholas M. Pajewski, Rowena J. Dolor, Mary Ann Sellers, Letitia H. Perdue, Sheronda R. Peeples, Adam M. Henrie, Nancy Woolard, W. Schuyler Jones, Catherine P. Benziger, Ariela R. Orkaby, Amanda S. Mixon, Jeffrey J. VanWormer, Michael D. Shapiro, Christine E. Kistler, Tamar S. Polonsky, Ranee Chatterjee, Alanna M. Chamberlain, Daniel E. FormanKirk U. Knowlton, Thomas M. Gill, L. Kristin Newby, Bradley G. Hammill, Mine S. Cicek, Neely A. Williams, Jake E. Decker, Jiafu Ou, Jack Rubinstein, Gaurav Choudhary, Raúl J. Gazmuri, Kenneth E. Schmader, Christianne L. Roumie, Camille P. Vaughan, Mark B. Effron, Rhonda M. Cooper-DeHoff, Mark A. Supiano, Raj C. Shah, Jeffrey C. Whittle, Adrian F. Hernandez, Walter T. Ambrosius, Jeff D. Williamson, Karen P. Alexander, Sergei Romashkan, Larry Fine, Mark Weiner, Rhonda Cooper-DeHoff, Schuyler Jones, Kate Callahan, Sara Espinoza, Jack Rubinstein, Heather Snyder, Maria Carrillo, Russell Rothman, Betsy Shenkman, Tom Carton, Beth Nauman, Kathleen McTique, Minnie Jefferson, John Wing, Shirley Bloodworth, Alva Owens, Linda Bordelon, Murray Heimberg, Jesse Massey, Miriam Gonzalez, Bob Brashears, Konrad Kaczkowski, Mark King, Kimberly Hoisington, Jeanette Lovato, Julissa Almonte, Jack White, Michael Gaziano, Laura Lovato, Krishna Poddar, Zachary Taylor, David Hunt, Jennifer Hervey, Michelle Kelsey, Renee Leverty, Bryan Batch, Al Richmond, Manda Hufstedler, Alain Chang, Joanne Hetzel, Melissa Laffey, Marco Pahor, Denise Houston, Dalane Kitzman, Steve Rapp, Bonnie Sachs, Scott Lang, Randy Nulph, Emily Rives, Susan Zieman, Anne Newman, Karina Kapitanovsky, David Reboussin, Mina Cicek, Katie Halverson, Sarah Gaussoin, Claire Dohner, Pamela Monds, Clint Alred, Jennifer Bowman, Julie Bunke, Nancie Deckard, Tammy Lowe, Ryan Thiel, Kyra VanDoren, Heidi Whiteside, David Reuben, Peter Peduzzi, Scott Solomon, Hermes Florez, John Breitner, Phil Greenland, Tom Travison, Russ Waitman, Michael Bancks, Katie Burnet, Andrew Telzak, Yessica Estrella Vanterpool, Sandra Oberembt, Irena Davies, Lindsay Shade, Kelsey Strout, Heather Kitzman, Meera Patel, Goutham Rao, Kelsey Ufholz, Sohail Rao, Esmeralda Cardoso, Jenifer Allen, Ambar Kulshreshtha, William Brown, Shanelle Cripps, Daniel Ford, Megan Gauvey-Kern, Angela Meilander, Diane Kohnhorst, Steven Rosas, Joshua Druckrey, Thomas Loepfe, Jodi Kaseno, Madeline Berendt, Richmond Akatue, Steven Houtschilt, Jeff Linder, Tiffany Brown, Lydia Bazzano, Shannon Williams, Seuli Brill, Matthew Jindra, Erin Yurko, Mehta Tapan, Leigh Kirkwood, Gohar Azhar, Amanda Pangle, Matthew Carlson, Jane Lu, Brandi Wells, Howard Gordon, Naomi Ashley, Michael Ernst, Kristin Grdinovac, Erica Lower, Jennifer Hart, Olveen Carrasquillo, Veronica Linares, Michael Hall, Lane Boyer, Kristin Hahn-Cover, Vickie Grieshaber, Alfred Fisher, Sarah Kirke, Jeannie Ake, Emily Klawson, Jessica Lee, Kim Johnson, Nicolas Musi, Kevin Brown, Craig Rubin, Gentina Thompson, Haddy Bah, Jennifer Wharton, Michele Wall, Ezequiel Zamora, Jesus Betancourt, Ellen Binder, Amy Young, Parag Goyal, Fernando Park, Aimee Almonte, Cynthia Carlsson, Hannah Zylstra, Andres Munoz, Ariana Tinker, Kyaw Soe, Jodie Ann Clarke

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Whether initiation of statins could increase survival free of dementia and disability in adults aged ≥75 years is unknown. PREVENTABLE, a double-blind, placebo-controlled randomized pragmatic clinical trial, will compare high-intensity statin therapy (atorvastatin 40 mg) with placebo in 20,000 community-dwelling adults aged ≥75 years without cardiovascular disease, disability, or dementia at baseline. Exclusion criteria include statin use in the prior year or for >5 years and inability to take a statin. Potential participants are identified using computable phenotypes derived from the electronic health record and local referrals from the community. Participants will undergo baseline cognitive testing, with physical testing and a blinded lipid panel if feasible. Cognitive testing and disability screening will be conducted annually. Multiple data sources will be queried for cardiovascular events, dementia, and disability; survival is site-reported and supplemented by a National Death Index search. The primary outcome is survival free of new dementia or persisting disability. Co-secondary outcomes are a composite of cardiovascular death, hospitalization for unstable angina or myocardial infarction, heart failure, stroke, or coronary revascularization; and a composite of mild cognitive impairment or dementia. Ancillary studies will offer mechanistic insights into the effects of statins on key outcomes. Biorepository samples are obtained and stored for future study. These results will inform the benefit of statins for increasing survival free of dementia and disability among older adults. This is a pioneering pragmatic study testing important questions with low participant burden to align with the needs of the growing population of older adults.

Original languageEnglish
Pages (from-to)1701-1713
Number of pages13
JournalJournal of the American Geriatrics Society
Volume71
Issue number6
DOIs
StatePublished - Jun 2023

Keywords

  • cognition
  • dementia
  • healthy aging
  • older adults
  • statins

Fingerprint

Dive into the research topics of 'Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale'. Together they form a unique fingerprint.

Cite this